These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38160837)

  • 21. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8.
    Toosi S; Orlow SJ; Manga P
    J Invest Dermatol; 2012 Nov; 132(11):2601-9. PubMed ID: 22696056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DEDuCT 2.0: An updated knowledgebase and an exploration of the current regulations and guidelines from the perspective of endocrine disrupting chemicals.
    Karthikeyan BS; Ravichandran J; Aparna SR; Samal A
    Chemosphere; 2021 Mar; 267():128898. PubMed ID: 33190914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ExHuMId: A curated resource and analysis of Exposome of Human Milk across India.
    Karthikeyan BS; Ravichandran J; Aparna SR; Samal A
    Chemosphere; 2021 May; 271():129583. PubMed ID: 33460906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent investigations on vitiligo vulgaris.
    Nordlund JJ; Majumder PP
    Dermatol Clin; 1997 Jan; 15(1):69-78. PubMed ID: 9001862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frontiers and controversies in the pathobiology of vitiligo: separating the wheat from the chaff.
    Boissy RE; Spritz RA
    Exp Dermatol; 2009 Jul; 18(7):583-5. PubMed ID: 19320739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autoimmunity in vitiligo: Therapeutic implications and opportunities.
    Khaitan BK; Sindhuja T
    Autoimmun Rev; 2022 Jan; 21(1):102932. PubMed ID: 34506987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into immune mechanisms of vitiligo.
    Boniface K; Taïeb A; Seneschal J
    G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitiligo.
    Kovacs SO
    J Am Acad Dermatol; 1998 May; 38(5 Pt 1):647-66; quiz 667-8. PubMed ID: 9591808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem Cell Therapy Offers a Possible Safe and Promising Alternative Approach for Treating Vitiligo: A Review.
    Esquivel D; Mishra R; Srivastava A
    Curr Pharm Des; 2020; 26(37):4815-4821. PubMed ID: 32744962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two Cases of Vitiligo Developed on the Persisting Dermal Melanocytosis: Is There a Difference between Epidermal Melanocytes and Dermal Melanocytes?
    Ahn JJ; Lee JH; Shin MK; Lee MH
    Ann Dermatol; 2013 May; 25(2):226-8. PubMed ID: 23717017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modern vitiligo genetics sheds new light on an ancient disease.
    Spritz RA
    J Dermatol; 2013 May; 40(5):310-8. PubMed ID: 23668538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Promising Role of Chemokines in Vitiligo: From Oxidative Stress to the Autoimmune Response.
    He S; Xu J; Wu J
    Oxid Med Cell Longev; 2022; 2022():8796735. PubMed ID: 35096274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of tumor necrosis factor-α in the pathogenesis of vitiligo.
    Camara-Lemarroy CR; Salas-Alanis JC
    Am J Clin Dermatol; 2013 Oct; 14(5):343-50. PubMed ID: 23912226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiopathology and genetics of vitiligo.
    Passeron T; Ortonne JP
    J Autoimmun; 2005; 25 Suppl():63-8. PubMed ID: 16298511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Vitiligo, no longer a fatality in 2023].
    Alvarez Martinez D; Bertold C; Passeron T; Cortes B
    Rev Med Suisse; 2023 Mar; 19(820):637-641. PubMed ID: 36988172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical analysis of melanocyte content in different zones of vitiligo lesions using the Melan-A marker.
    Kubanov A; Proshutinskaia D; Volnukhin V; Katunina O; Abramova T
    Acta Dermatovenerol Alp Pannonica Adriat; 2016; 25(1):5-9. PubMed ID: 27014772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic effects of EGCG on vitiligo.
    Zhu Y; Wang S; Lin F; Li Q; Xu A
    Fitoterapia; 2014 Dec; 99():243-51. PubMed ID: 25128425
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melanocytes and keratinocytes morphological changes in vitiligo patients. A histological, immunohistochemical and ultrastructural analysis.
    Elsherif R; Mahmoud WA; Mohamed RR
    Ultrastruct Pathol; 2022 Mar; 46(2):217-235. PubMed ID: 35243959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal analyses of vitiligo skin identify tissue characteristics of stable disease.
    Shiu J; Zhang L; Lentsch G; Flesher JL; Jin S; Polleys C; Jo SJ; Mizzoni C; Mobasher P; Kwan J; Rius-Diaz F; Tromberg BJ; Georgakoudi I; Nie Q; Balu M; Ganesan AK
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35653192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.